Thyroid Neoplasms

The grounding supports a genetic basis for thyroid tumorigenesis and progression, with BRAF mutation described as a common oncogenic alteration in thyroid cancer. It also notes mutation-specific disease subsets such as BRAF-mutated anaplastic thyroid cancer and NTRK-fusion thyroid cancer, but does not support broader causal claims beyond these molecular alterations.

The literature describes thyroid cancer as driven by genetic alterations that promote tumorigenesis and progression. BRAF mutation is presented as an independent oncogenic event, and the tumor microenvironment is also a studied mechanism in thyroid neoplasms. The grounding additionally indicates that thyroid cancer biology includes distinct molecular subtypes defined by alterations such as BRAF and NTRK fusions.

The supplied grounding does not support general clinical risk factors for thyroid neoplasms. It does indicate molecular features associated with disease subtypes, including BRAF mutation and NTRK fusion, but these are not presented as population-level risk factors.

Management is described at the level of surgery, radiotherapy, and systemic therapy for differentiated and advanced thyroid cancer. For advanced disease, the literature highlights antiangiogenic multikinase inhibitors such as vandetanib, cabozantinib, sorafenib, and lenvatinib, as well as mutation-specific targeted therapy including dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. The grounding also mentions thyroid cancer guidelines for diagnosis and management, but does not provide enough detail to support more specific treatment categories beyond these modalities.